1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Spinal Muscular Atrophy (SMA)-Pipeline Insights, 2017


DelveInsight’s, “ Spinal Muscular Atrophy (SMA)-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Spinal Muscular Atrophy (SMA). The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Spinal Muscular Atrophy (SMA). DelveInsight’s Report also assesses the Spinal Muscular Atrophy (SMA) therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Spinal Muscular Atrophy (SMA)
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Spinal Muscular Atrophy (SMA) pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Spinal Muscular Atrophy (SMA) and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Spinal Muscular Atrophy (SMA)-Pipeline Insights, 2017
Illustrative

- Spinal Muscular Atrophy (SMA) Overview
- Spinal Muscular Atrophy (SMA) Pipeline Therapeutics
- Spinal Muscular Atrophy (SMA) Therapeutics under Development by Companies
- Spinal Muscular Atrophy (SMA) Filed and Phase III Products
- Comparative Analysis
- Spinal Muscular Atrophy (SMA) Phase II Products
- Comparative Analysis
- Spinal Muscular Atrophy (SMA) Phase I and IND Filed Products
- Comparative Analysis
- Spinal Muscular Atrophy (SMA) Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Spinal Muscular Atrophy (SMA) - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Spinal Muscular Atrophy (SMA) - Discontinued Products
- Spinal Muscular Atrophy (SMA) - Dormant Products
- Companies Involved in Therapeutics Development for Spinal Muscular Atrophy (SMA)
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Spinal Muscular Atrophy (SMA), 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Spinal Muscular Atrophy (SMA) Assessment by Monotherapy Products
- Spinal Muscular Atrophy (SMA) Assessment by Combination Products
- Spinal Muscular Atrophy (SMA) Assessment by Route of Administration
- Spinal Muscular Atrophy (SMA) Assessment by Stage and Route of Administration
- Spinal Muscular Atrophy (SMA) Assessment by Molecule Type
- Spinal Muscular Atrophy (SMA) Assessment by Stage and Molecule Type
- Spinal Muscular Atrophy (SMA) Therapeutics - Discontinued Products
- Spinal Muscular Atrophy (SMA) Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Spinal Muscular Atrophy (SMA), 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Spinal Muscular Atrophy (SMA) Assessment by Monotherapy Products
- Spinal Muscular Atrophy (SMA) Assessment by Combination Products
- Spinal Muscular Atrophy (SMA) Assessment by Route of Administration
- Spinal Muscular Atrophy (SMA) Assessment by Stage and Route of Administration
- Spinal Muscular Atrophy (SMA) Assessment by Molecule Type
- Spinal Muscular Atrophy (SMA) Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Neurological Disorder Drugs Market - Europe Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Europe Neurological Disorder Drugs Market: Overview This report on the neurological disorder drugs market studies the current as well as future prospects of the market in Europe. Health concern related ...

Epiomic Epidemiology Series: Bell%s Palsy Forecast in 15 Major Markets 2017-2027

Epiomic Epidemiology Series: Bell%s Palsy Forecast in 15 Major Markets 2017-2027

  • $ 5112
  • Industry report
  • February 2017
  • by Black Swan Analysis Ltd

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Bell’s palsy in 15 Major Markets Bell's palsy, also known as idiopathic facial nerve palsy, is a weakness of the muscles on one side ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.